MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$141,344K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Net income (loss)
Deferred income taxes
Share-based compensation expense
Others
Negative Cash Flow Breakdown
Repayment of 2026 convertible no...
Accounts receivable, net
Accounts payable and accrued exp...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
51,291
40,773
-2,276
40,080
Depreciation and amortization
457
443
460
475
Loss on disposal of property and equipment
-
-
3
-7
Share-based compensation expense
3,236
3,653
3,823
3,612
Non-cash interest expense
389
419
418
418
Non-cash lease expense
453
444
435
426
Deferred income taxes
15,173
19,196
-1,746
27,772
Accounts receivable, net
6,890
59,097
-73,623
34,193
Prepaid expenses and other current assets
1,416
-5,997
-1,086
248
Other assets
-17
-121
-100
-63
Accounts payable and accrued expenses
-4,614
-4,886
-318
10,693
Accrued research and development costs
1,124
-1,102
-274
-1,168
Operating lease liabilities
-635
-621
-612
-603
Other liabilities
-309
-219
-141
249
Net cash provided by operating activities
58,276
5,121
74,575
47,583
Purchases of property and equipment
-
-
-1
2
Net cash used in investing activities
-
-
1
-2
Proceeds from employee stock purchase plan
303
-
122
0
Repayment of 2026 convertible notes
200,000
-
-
-
Net cash provided by (used in) financing activities
-199,697
-
122
0
Effect of exchange rate changes on cash and cash equivalents
77
-106
351
-26
Net increase (decrease) in cash and cash equivalents
-141,344
5,015
75,049
47,555
Cash and cash equivalents, beginning of period
220,471
215,456
140,407
88,559
Cash and cash equivalents, end of period
79,127
220,471
215,456
140,407
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net income (loss)
$51,291K
(472.02%↑ Y/Y)
Deferred income taxes
$15,173K
(2.69%↑ Y/Y)
Share-based compensation
expense
$3,236K
(-67.03%↓ Y/Y)
Accrued research and
development costs
$1,124K
(142.19%↑ Y/Y)
Depreciation and
amortization
$457K
(-51.69%↓ Y/Y)
Non-cash lease expense
$453K
(-45.22%↓ Y/Y)
Non-cash interest
expense
$389K
(-53.25%↓ Y/Y)
Other assets
-$17K
(94.01%↑ Y/Y)
Net cash provided by
operating activities
$58,276K
(1092.71%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
$77K
(111.77%↑ Y/Y)
Canceled cashflow
$13,864K
Net increase
(decrease) in cash and cash...
-$141,344K
(-3392.43%↓ Y/Y)
Canceled cashflow
$58,353K
Proceeds from employee
stock purchase plan
$303K
(222.34%↑ Y/Y)
Accounts receivable, net
$6,890K
(60.91%↑ Y/Y)
Accounts payable and
accrued expenses
-$4,614K
(-10.54%↓ Y/Y)
Prepaid expenses and
other current assets
$1,416K
(200.64%↑ Y/Y)
Operating lease
liabilities
-$635K
(45.07%↑ Y/Y)
Other liabilities
-$309K
(-108.01%↓ Y/Y)
Net cash provided by
(used in) financing...
-$199,697K
(-212543.62%↓ Y/Y)
Canceled cashflow
$303K
Repayment of 2026
convertible notes
$200,000K
Buy us a coffee
IRONWOOD PHARMACEUTICALS INC (IRWD)
IRONWOOD PHARMACEUTICALS INC (IRWD)